Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to guide recommendations for adjuvant immune checkpoint inhibitor (ICI) therapy. ctDNA helps monitor minimal residual disease and early treatment response while tissue PD-L1 status aids in predicting ICI efficacy, optimizing patient treatment plans.

EP: 1.MIUC: Risk of Recurrence After Radical Cystectomy

EP: 2.High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

EP: 3.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

EP: 4.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

EP: 5.Dr. Galsky’s Perspectives on the CheckMate 274 Data Results

EP: 6.Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

Now Viewing

EP: 7.Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

EP: 8.Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

EP: 9.Adjuvant ICI for High-Risk MIUC: Patient Counseling

EP: 10.Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

Video content above is prompted by the following:

• Are you using ctDNA and/or tissue PD-L1 to guide recommendations for adjuvant ICI and/or to monitor response to adjuvant ICI?

Recent Videos